Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00150072
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2005-09-07
Brief Title:
Efficacy and Safety of Imatinib in Chordoma
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Phase II Study of Imatinib Mesylate in Chordoma
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Preliminary response data observed by Casali Cancer 2004 with imatinib 800 mgday in patients affected by chordoma need to be confirmed by a Phase II study whose primary endpoint will be the formal assessment of clinical and pathological response Aim of the study will be to explore treatments activity but also the potential impact of tumor response the feasibility and outcome of subsequent surgery and radiotherapy In addition patterns of tumour response need to be investigated as well given the peculiar patterns of response shown with molecular-targeted therapy in solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None